Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 11:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Phentermine-Topiramate Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects

NCT02229214
View directory record Official record
Conditions
Obesity
Interventions
Qsymia, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Sep 23, 2026, 11:31 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate

NCT01950520
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Propranolol, Pindolol, Dantrolene, Magnesium Sulfate, Caffeine, Qsymia, Topiramate, Phentermine, Naltrexone, Mirabegron 50mg, Mirabegron 200mg, Placebo Cohort 1, Placebo Cohort 2, Placebo for Mirabegron
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 35 Years · Male only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 23, 2026, 11:31 PM EDT
Completed Phase 4 Interventional Results available

A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents

NCT02714062
View directory record Official record
Conditions
Pediatric Obesity, Childhood Obesity
Interventions
Placebo, VI-0521 Mid Dose, VI-0521 Top Dose
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Baton Rouge, Louisiana • Marrero, Louisiana • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Sep 23, 2026, 11:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.

NCT00842400
View directory record Official record
Conditions
Obesity
Interventions
Metformin, VI-0521, Sitagliptan, Probenecid
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Sep 23, 2026, 11:31 PM EDT
Recruiting Phase 4 Interventional

Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery

NCT05975580
View directory record Official record
Conditions
Obesity
Interventions
Topiramate, Phentermine, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 23, 2026, 11:31 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Phentermine/Topiramate as Preventive Pharmacotherapy for Obesity

NCT05834062
View directory record Official record
Conditions
Obesity, Adolescent
Interventions
Qsymia and lifestyle management therapy, Placebo and lifestyle management therapy
Drug · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
16 Years to 22 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 23, 2026, 11:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Topiramate-Phentermine Combinations for Cocaine Dependence

NCT02239913
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Cocaine, Placebo, Phentermine, Topiramate
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 23, 2026, 11:31 PM EDT
Completed Phase 2 Interventional

Phentermine/Topiramate Extended Release in Binge Eating Disorder (BED)

NCT02659475
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
PHEN/TPM ER (Qsymia®)
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Sep 23, 2026, 11:31 PM EDT
Withdrawn Phase 2 Interventional

Medications After Adolescent Bariatric Surgery

NCT04572217
View directory record Official record
Conditions
Pediatric Obesity
Interventions
Topiramate, Phentermine
Drug
Lead sponsor
Janey Pratt
Other
Eligibility
12 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Sep 23, 2026, 11:31 PM EDT
Completed Phase 2 Interventional Results available

Phentermine/Topiramate for Uric Acid Stones

NCT04621929
View directory record Official record
Conditions
Obesity, Uric Acid Stones, Type 2 Diabetes Mellitus in Obese, Pre-Diabetes
Interventions
Phentermine / Topiramate Oral Product, Citrate Salts, Allopurinol, Diet
Drug · Combination Product
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 23, 2026, 11:31 PM EDT
Completed Phase 4 Interventional Results available

Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity

NCT03799198
View directory record Official record
Conditions
Obesity
Interventions
Weight Management Program (WMP), Medication for chronic weight management (Rx)
Other · Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 23, 2026, 11:31 PM EDT
Terminated Phase 2 Interventional Results available

Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults

NCT00737633
View directory record Official record
Conditions
Diabetes
Interventions
VI-0521
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 70 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 23, 2026, 11:31 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults

NCT00563368
View directory record Official record
Conditions
Obesity
Interventions
VI-0521, topiramate, phentermine
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2015 · Synced Sep 23, 2026, 11:31 PM EDT
Completed Phase 2 Interventional Results available

Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics

NCT00486291
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
VI-0521, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 23, 2026, 11:31 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Anti-Obesity Phentermine-Topiramate Extended Release Pharmacotherapy vs Placebo Among Patients Using a Wearable Activity Tracker

NCT04408586
View directory record Official record
Conditions
Obesity
Interventions
Phentermine-Topiramate Extended Release, Placebo, Online support system
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 23, 2026, 11:31 PM EDT
Withdrawn Not applicable Interventional

Comparison of the Effect of Intense-Exercise/Moderate-Calorie, Topiramate-Phentermine and Cognitive Behavioral Therapy on Obesity

NCT01970566
View directory record Official record
Conditions
Obesity, Diabetes Mellitus
Interventions
Behavioral and Drug, Behavioral
Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
20 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Sep 23, 2026, 11:31 PM EDT
Active, not recruiting No phase listed Observational

Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

NCT07188545
View directory record Official record
Conditions
Cardiovascular Kidney Metabolic Syndrome
Interventions
Intervention, Active Comparator
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
23,280,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 23, 2026, 11:31 PM EDT
Terminated Phase 4 Interventional Results available

EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

NCT04531176
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Weight Management Program (WMP), Traditional care, Phentermine / Topiramate Extended Release Oral Capsule, naltrexone/bupropion extended-release, liraglutide 3.0 mg, Orlistat
Other · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 23, 2026, 11:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults

NCT00518466
View directory record Official record
Conditions
Obesity
Interventions
topiramate, phentermine
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 23, 2026, 11:31 PM EDT
Completed Phase 3 Interventional Results available

Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults

NCT00554216
View directory record Official record
Conditions
Obesity
Interventions
VI-0521, Placebo matched phentermine/topiramate
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
5
States / cities
San Diego, California • Ridgefield, Connecticut • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 23, 2026, 11:31 PM EDT
Not yet recruiting Phase 2 Interventional

Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma

NCT07790913
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia in Remission, Hodgkin Lymphoma in Remission, Non-Hodgkin Lymphoma in Remission, Cancer Survivorship
Interventions
Phentermine/Topiramate ER, Health Behavior and Lifestyle Counseling
Drug · Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Years to 24 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 23, 2026, 11:31 PM EDT
Active, not recruiting Early Phase 1 Interventional Results available

Phentermine/Topiramate in Adolescents With Type 2 Diabetes and Obesity

NCT04881799
View directory record Official record
Conditions
Pediatric Obesity
Interventions
Phentermine/Topiramate (Qsymia), Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 20 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 23, 2026, 11:31 PM EDT
Completed Phase 4 Interventional Results available

Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy

NCT01087736
View directory record Official record
Conditions
PTSD, Alcohol Abuse, Alcoholism
Interventions
Topiramate, Placebo administration
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Sep 23, 2026, 11:31 PM EDT
Active, not recruiting No phase listed Observational

Anti-obesity Pharmacotherapy and Inflammation

NCT05756764
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide, Phentermine-Topiramate combination, Phentermine, Tirzepatide, Topiramate, Diethylpropion, Naltrexone/Bupropion, Liraglutide
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
35 Years to 60 Years
Enrollment
30 participants
Timeline
2023 – 2026
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 23, 2026, 11:31 PM EDT